Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

Sponsor
Northern Jiangsu People's Hospital
Study ID
NCT07461532
Status
Recruiting
Apply to this trial

Conditions

  • Cirrhosis
  • Hypertension, Portal
  • Portal Vein Thrombosis
  • Splenectomy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apixaban 2.5 MG — DRUG
    If portal vein thrombosis occurs more than one year after laparoscopic splenectomy and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.

Study Details

The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.

Key Dates

First listed
Mar 10, 2026
Start date
Apr 1, 2026
Status verified
Mar 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apixaban group
    If portal vein thrombosis occurs more than one year after laparoscopic splenectomy and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.

Primary Outcome Measure

Proportion of complete recanalization of portal vein thrombosis [ Time Frame: Follow-up of 6 months or greater ]

Central Contacts

Related Studies